No Data
No Data
Tariffs Expected to Bring Pharmaceutical Price Bumps, Shortages -- Market Talk
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Express News | Mira Pharmaceuticals Inc - Submits Ind Application to FDA for Ketamir-2
Express News | Mira Pharmaceuticals Inc: Submission of Investigational New Drug (Ind) Application by End of 2024
EXCLUSIVE: Mira Pharmaceuticals Tells Benzinga 'Advancing Ketamir-2 Into Clinical Trials as Quickly as Possible Reflects Our Strategic Focus on Generating Proof-of-concept Data That Positions MIRA for a Potential M&A Transaction or Strategic Partnership'